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Abstract 
Following a haemorrhagic stroke, it is uncertain whether this event scores 1 point (either for Stroke 
or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We 
investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a 
haemorrhagic stroke. 
We analysed data from the Danish nationwide cohort of incident atrial fibrillation (AF) patients 
from January 1999 to December 2013. The primary outcome in this observational study was major 
bleeding. The original- and the recalibrated HAS-BLED scores were assessed and event rates of 
major bleeding were calculated. We compared the predictive accuracy of major bleeding by C-
statistics, the Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI). 
In a total of 210,299 AF patients, we observed an event rate for major bleeding of 4.3 per 100 
person-years. The C-statistics for the two scores were modest: 0.613 (95%CI, 0.607-0.619) for the 
original and 0.616 (95%CI, 0.610-0.622) for the recalibrated. The NRI was 10.0% (95%CI 7.6%-
12.4%). When assessing the NRI in less than 6 months follow-up, we observed a markedly higher 
NRI of 34.2%. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) reflecting that the recalibrated 
HAS-BLED score more accurately predicted bleeding events. 
Recalibration of the “S” component in the HAS-BLED score, counting 2 points for a haemorrhagic 
stroke, resulted in an increase in the C-statistics, NRI and IDI. This approach could potentially aid 
physicians in a more accurate bleeding risk assessment in AF patients. 
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Introduction 
Oral anticoagulant (OAC) treatment substantially reduces the risk of stroke and all-cause mortality 
in atrial fibrillation (AF) patients.1 However, the decision to treat these patients relies on the 
expected risk of stroke weighed against the expected risk of bleeding. Contemporary guideline 
recommendations on OAC treatment are based on the CHA2DS2-VASc score (assessing the risk of 
thromboembolism) to initiate treatment or not.2,3 The European Society of Cardiology further 
recommends formal assessment of the bleeding risk by the HAS-BLED score.4 The HAS-BLED 
score summarizes to a maximum of 9 points (hypertension, abnormal renal/liver function [1 or 2 
points], stroke, bleeding history or predisposition, labile INR, elderly [>65], drugs/alcohol 
concomitantly [1 or 2 points]).5 A stroke currently contributes 1 point, and prior major bleeding (or 
its predisposition) contributes 1 point. Accurate bleeding risk assessment and optimal treatment 
guidance is pivotal in this frail population of AF patients who sustain an intracranial bleeding, 
especially given the strong associations to disability and mortality. 6,7 
Following a haemorrhagic stroke, it is it is unclear whether it should count 1 point (either for Stroke 
or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We 
investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a 
haemorrhagic stroke.
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Methods and materials 
We used data from three Danish nationwide registries to conduct an observational cohort study 
investigating the original HAS-BLED score and the recalibrated HAS-BLED score. As previously 
done, we identified nonvalvular AF patients discharged from hospital from January 1st 1999 to 
December 31st 2013, and excluded patients who encountered a thromboembolism or major bleeding 
within 7 days after discharged.8 The primary endpoint was major bleeding defined as a composite of 
intracranial bleeding (including traumatic intracranial bleeding events), gastrointestinal bleeding, 
acute anemia, bleeding from the urinary tract, and airway bleeding; see supplemental e-Table 1 for 
ICD-10 codes. Both primary and secondary diagnoses were included, but emergency room 
diagnoses were not included due to low validity. 9 We followed the patients from 7 days after 
hospital discharge and up to one year later or to occurrence of death, a major bleeding event, or end-
of-study period, whichever came first.  
We calculated two different HAS-BLED scores (original and recalibrated) at hospital discharge; 
only patients with a haemorrhagic stroke (non-traumatic intracranial bleeds) were reclassified in the 
recalibrated HAS-BLED score. Crude event rates (total number of events divided by accrued 
person-time) stratified by score ranging from 0-8 were reported. We did not have information on 
INR values; hence the “L” component was excluded from the calculations. To compare the 
predictive power of the scores we calculated and compared the (Harrell’s) C-statistics.10 We 
obtained estimates of bleeding risk in a competing risk of death setting, by using information 
directly from the cumulative incidence function.11 Use of competing risk analyses are advised - 
especially in an elderly and fragile population - to obtain adequate risk estimates, which are not 
biased due to the competing risk.12 To further compare the individual level changes in risk 
assessment from the two scores, we calculated a Net Reclassification Index (NRI), also in a 
competing risk setting.13,14 In short, the NRI evaluates the proportion of patients with a 
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correct/incorrect change in risk according to being a case (patient with an event) or a non-case. 
Finally, we calculated the Integrated Discrimination Improvement (IDI) relative to the original 
HAS-BLED score to assess the separation in predicted risk for events and non-events.15 Bootstrap 
confidence intervals (CI) for C-statistics, NRI and IDI were calculated using 100 bootstrap samples. 
Data were analysed using Stata version 13.1 (Stata Corporation, College Station, TX). Register-
based studies do not require ethical approval in Denmark. 
We performed three sensitivity analyses, as follows: 1) stratifying patients according to baseline 
OAC treatment or initiation within the first 7 days after baseline. This was done in an attempt to 
indirectly assess if the missing “L” component from the data could influence the results 
(recognizing that patients not treated with OAC would not contribute to this component); 2) 
restricting the follow-up time to 6 months to assess performance of the recalibrated HAS-BLED 
compared to the original HAS-BLED in (relatively) short follow-up time. The motivation for this 
analysis was established by conceding an intracranial haemorrhage can be associated with increased 
event rates of recurrent major bleeding (including recurrent intracranial bleeding)16; and 3), we 
restricted the study period to the five most recent calendar years (2009-2013). Given the increasing 
availability of imaging technologies (MRI/CT scans) in this period, the validity of haemorrhagic 
stroke and/or haemorrhagic bleedings diagnosis were deemed to increase; hence, the proportion of 
reclassified patients (based on haemorrhagic stroke) would be more accurate.  
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Results 
The study population comprised 210,299 AF patients (5,898 patients were excluded due to a 
thromboembolic/bleeding event within 7 days after discharge) with a median age of 74 [IQR: 65-
82] and 46.6% were women. During one year of follow-up we observed 7,602 (3.62%) bleeding 
events. The mean HAS-BLED scores were 2.13 for the original score and 2.14 for the recalibrated 
score. The overall crude event rate of the primary endpoint was 4.3 per 100 person-years; Table 1 
shows the event rates stratified according to points for the two scores. A total of 1,479 patients were 
reclassified in the recalibrated HAS-BLED score based on having sustained a haemorrhagic stroke 
when the observation time commenced. The predictive accuracy of the two scores in terms of the C-
statistics was moderate, 0.613 (95%CI, 0.607-0.619) for the original and 0.616 (95%CI, 0.610-
0.622) for the recalibrated HAS-BLED score, respectively. The NRI was 10.0% (95%CI, 7.6%-
12.4%) displaying a significant improvement of correct classification by the recalibrated HAS-
BLED scored compared to the original score. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) 
reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events. 
When stratifying the cohort to patients who received no OAC treatment vs treated, we saw an 
increase in the bleeding rates per 100 person-years: 3.97 for no treatment and 4.73 for OAC treated. 
The sensitivity analysis resulted in similar NRI: for OAC treated 9.0% (95%CI, 4.8%-12.3%) and 
for not treated 10.1% (95%CI, 9.0%-11.2%). The C-statistics were likewise not affected by this 
stratification [data not shown]. When applying shorter follow-up period (i.e. 6 months), we 
observed a considerably higher NRI of 35.0% (95%CI, 32.9%-37.1%). The C-statistics for original 
and recalibrated HAS-BLED score, however, displayed a modest increase, 0.617 and 0.621, 
respectively. Restricting the study period to the last five years reduced the study population to 
78,699 patients, and essentially doubled the NRI: 20.7% (95%CI, 17.9%-23.5%). 
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Discussion 
In this nationwide cohort study reflecting clinical practice, we recalibrated the original HAS-BLED 
score to account for 2 points if the stroke type was a haemorrhagic stroke. We observed an 
improved accuracy of the recalibrated HAS-BLED score as displayed by an improved NRI of 
10.0% and a relative IDI of 23%. 
Although the recalibration only resulted in a modest increase in the C-statistics, the potential of 
improved accuracy could be higher, as we only reclassified a very small proportion of this large 
cohort: of 2,218 patients who sustained an ICH event, we reclassified 1,479 (0.7% of total study 
population). The remaining 739 patients who were not reclassified all had prior events of ischemic 
stroke/TIA and a major bleeding event (or anaemia).  
The recalibrated HAS-BLED score could potentially be more complicated to count than the original 
score. The physician who is presented with a patient who has sustain an haemorrhagic stroke has to 
take into account if this patient already has 1 point attributing prior bleeding and prior stroke. On 
the other hand, counting a haemorrhagic stroke as two points (1 for stroke and 1 for bleeding) 
appears intuitively applicable given the nature of the outcome.  Importantly, the recalibrated score 
performs best within short follow-up time in terms of NRI, which could be related to the patients 
who were actually reclassified (those with a haemorrhagic stroke); however, this could represent the 
early excess risk associated with such ‘high risk’ patients. 
This study has some limitations. We did not have access to INR values from the registries; hence 
we excluded a potential pivotal component from the HAS-BLED score. We used an observational 
design to assess the HAS-BLED score, but we cannot rule out miscoding of comorbidity and 
concomitant medication.  Additionally, we did not have access to imaging data and we cannot rule 
out erroneously coded haemorrhagic strokes. We assessed the HAS-BLED score at baseline, 
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however risk assessment in AF patients is a continuum and risk (both for bleeding and 
thromboembolic events) does not remain static in these patients.  
In conclusion, recalibration of the HAS-BLED score, counting 2 points for a haemorrhagic stroke, 
resulted in an improved accuracy of predicting major bleeding events. This approach could 
potentially aid physicians in a more accurate bleeding risk assessment in AF patients. 
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Table 1: Major bleeding event rates per 100 person-years for major bleeding events according to 
HAS-BLED scores for 1-year follow-up in incident atrial fibrillation patients. 
 Original HASBLED  Recalibrated HASBLED 
Points Person-time Events Event rate Person-time Events Event rate 
0 19611        193   0.98 19611        193 .98 
1 41864       1127   2.69 41799       1,111 2.69 
2 51933       2179   4.20 51703       2,149 4.16 
3 43769       2392   5.46 43646       2,368 5.43 
4 17359       1294   7.45 17472       1,316 7.53 
5 3692        361   9.78 3965       402 10.14 
6 425         52   12.25 456         59 12.94 
7 22         4 18.23 23          4 17.36 
8 12 0 - 22          0 - 
9 (Labile INR) NA NA NA NA NA NA 
Any score 
 
178676 7602 4.3 - - - 
Categorised risk       
0-2 (low risk) 113408 3499 3.09 113113 3453 3.05 
≥3 (High risk) 65268 4103 6.29 65563 4149 6.33 
Observation time starts after a quarantine period of 7 days relative to AF discharge. 
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List of abbreviations: 
OAC: Oral anticoagulant   
AF: Atrial fibrillation  
ICD-10: International classification of disease version 10 
INR: International normalized ratio  
NRI: Net reclassification index 
IDI: Integrated discrimination improvement 
CI: Confidence interval 
IQR: Interquartile range 
TIA: Transient ischemic attack 
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Abstract 
Following a haemorrhagic stroke, it is uncertain whether this event scores 1 point (either for Stroke 
or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We 
investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a 
haemorrhagic stroke. 
We analysed data from the Danish nationwide cohort of incident atrial fibrillation (AF) patients 
from January 1999 to December 2013. The primary outcome in this observational study was major 
bleeding. The original- and the recalibrated HAS-BLED scores were assessed and event rates of 
major bleeding were calculated. We compared the predictive accuracy of major bleeding by C-
statistics, the Net Reclassification Index (NRI) and Integrated Discrimination Improvement (IDI). 
In a total of 210,299 AF patients, we observed an event rate for major bleeding of 4.3 per 100 
person-years. The C-statistics for the two scores were modest: 0.613 (95%CI, 0.607-0.619) for the 
original and 0.616 (95%CI, 0.610-0.622) for the recalibrated. The NRI was 10.0% (95%CI 7.6%-
12.4%). When assessing the NRI in less than 6 months follow-up, we observed a markedly higher 
NRI of 34.2%. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) reflecting that the recalibrated 
HAS-BLED score more accurately predicted bleeding events. 
Recalibration of the “S” component in the HAS-BLED score, counting 2 points for a haemorrhagic 
stroke, resulted in an increase in the C-statistics, NRI and IDI. This approach could potentially aid 
physicians in a more accurate bleeding risk assessment in AF patients. 
  
Page 4 of 22
ScholarOne - http://mchelp.manuscriptcentral.com/gethelpnow/index.html - (434) 964-4100
CHEST
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Privileged Communication
Introduction 
Oral anticoagulant (OAC) treatment substantially reduces the risk of stroke and all-cause mortality 
in atrial fibrillation (AF) patients.
1
 However, the decision to treat these patients relies on the 
expected risk of stroke weighed against the expected risk of bleeding. Contemporary guideline 
recommendations on OAC treatment are based on the CHA2DS2-VASc score (assessing the risk of 
thromboembolism) to initiate treatment or not.
2,3
 The European Society of Cardiology further 
recommends formal assessment of the bleeding risk by the HAS-BLED score.
4
 The HAS-BLED 
score summarizes to a maximum of 9 points (hypertension, abnormal renal/liver function [1 or 2 
points], stroke, bleeding history or predisposition, labile INR, elderly [>65], drugs/alcohol 
concomitantly [1 or 2 points]).
5
 A stroke currently contributes 1 point, and prior major bleeding (or 
its predisposition) contributes 1 point. Accurate bleeding risk assessment and optimal treatment 
guidance is pivotal in this frail population of AF patients who sustain an intracranial bleeding, 
especially given the strong associations to disability and mortality. 
6,7
 
Following a haemorrhagic stroke, it is it is unclear whether it should count 1 point (either for Stroke 
or Bleeding) or 2 points (1 point each for Stroke and Bleeding) on the HAS-BLED score. We 
investigated the value of a recalibration of the HAS-BLED score to account for 2 points from a 
haemorrhagic stroke.
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Methods and materials 
We used data from three Danish nationwide registries to conduct an observational cohort study 
investigating the original HAS-BLED score and the recalibrated HAS-BLED score. As previously 
done, we identified nonvalvular AF patients discharged from hospital from January 1
st
 1999 to 
December 31
st
 2013, and excluded patients who encountered a thromboembolism or major bleeding 
within 7 days after discharged.
8
 The primary endpoint was major bleeding defined as a composite of 
intracranial bleeding (including traumatic intracranial bleeding events), gastrointestinal bleeding, 
acute anemia, bleeding from the urinary tract, and airway bleeding; see supplemental e-Table 1 for 
ICD-10 codes. Both primary and secondary diagnoses were included, but emergency room 
diagnoses were not included due to low validity. 
9
 We followed the patients from 7 days after 
hospital discharge and up to one year later or to occurrence of death, a major bleeding event, or end-
of-study period, whichever came first.  
We calculated two different HAS-BLED scores (original and recalibrated) at hospital discharge; 
only patients with a haemorrhagic stroke (non-traumatic intracranial bleeds) were reclassified in the 
recalibrated HAS-BLED score. Crude event rates (total number of events divided by accrued 
person-time) stratified by score ranging from 0-8 were reported. We did not have information on 
INR values; hence the “L” component was excluded from the calculations. To compare the 
predictive power of the scores we calculated and compared the (Harrell’s) C-statistics.
10
 We 
obtained estimates of bleeding risk in a competing risk of death setting, by using information 
directly from the cumulative incidence function.
11
 Use of competing risk analyses are advised - 
especially in an elderly and fragile population - to obtain adequate risk estimates, which are not 
biased due to the competing risk.
12
 To further compare the individual level changes in risk 
assessment from the two scores, we calculated a Net Reclassification Index (NRI), also in a 
competing risk setting.
13,14
 In short, the NRI evaluates the proportion of patients with a 
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correct/incorrect change in risk according to being a case (patient with an event) or a non-case. 
Finally, we calculated the Integrated Discrimination Improvement (IDI) relative to the original 
HAS-BLED score to assess the separation in predicted risk for events and non-events.
15
 Bootstrap 
confidence intervals (CI) for C-statistics, NRI and IDI were calculated using 100 bootstrap samples. 
Data were analysed using Stata version 13.1 (Stata Corporation, College Station, TX). Register-
based studies do not require ethical approval in Denmark. 
We performed three sensitivity analyses, as follows: 1) stratifying patients according to baseline 
OAC treatment or initiation within the first 7 days after baseline. This was done in an attempt to 
indirectly assess if the missing “L” component from the data could influence the results 
(recognizing that patients not treated with OAC would not contribute to this component); 2) 
restricting the follow-up time to 6 months to assess performance of the recalibrated HAS-BLED 
compared to the original HAS-BLED in (relatively) short follow-up time. The motivation for this 
analysis was established by conceding an intracranial haemorrhage can be associated with increased 
event rates of recurrent major bleeding (including recurrent intracranial bleeding)
16
; and 3), we 
restricted the study period to the five most recent calendar years (2009-2013). Given the increasing 
availability of imaging technologies (MRI/CT scans) in this period, the validity of haemorrhagic 
stroke and/or haemorrhagic bleedings diagnosis were deemed to increase; hence, the proportion of 
reclassified patients (based on haemorrhagic stroke) would be more accurate.  
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Results 
The study population comprised 210,299 AF patients (5,898 patients were excluded due to a 
thromboembolic/bleeding event within 7 days after discharge) with a median age of 74 [IQR: 65-
82] and 46.6% were women. During one year of follow-up we observed 7,602 (3.62%) bleeding 
events. The mean HAS-BLED scores were 2.13 for the original score and 2.14 for the recalibrated 
score. The overall crude event rate of the primary endpoint was 4.3 per 100 person-years; Table 1 
shows the event rates stratified according to points for the two scores. A total of 1,479 patients were 
reclassified in the recalibrated HAS-BLED score based on having sustained a haemorrhagic stroke 
when the observation time commenced. The predictive accuracy of the two scores in terms of the C-
statistics was moderate, 0.613 (95%CI, 0.607-0.619) for the original and 0.616 (95%CI, 0.610-
0.622) for the recalibrated HAS-BLED score, respectively. The NRI was 10.0% (95%CI, 7.6%-
12.4%) displaying a significant improvement of correct classification by the recalibrated HAS-
BLED scored compared to the original score. The relative IDI was 23.6% (95%CI, 15.7%-31.5%) 
reflecting that the recalibrated HAS-BLED score more accurately predicted bleeding events. 
When stratifying the cohort to patients who received no OAC treatment vs treated, we saw an 
increase in the bleeding rates per 100 person-years: 3.97 for no treatment and 4.73 for OAC treated. 
The sensitivity analysis resulted in similar NRI: for OAC treated 9.0% (95%CI, 4.8%-12.3%) and 
for not treated 10.1% (95%CI, 9.0%-11.2%). The C-statistics were likewise not affected by this 
stratification [data not shown]. When applying shorter follow-up period (i.e. 6 months), we 
observed a considerably higher NRI of 35.0% (95%CI, 32.9%-37.1%). The C-statistics for original 
and recalibrated HAS-BLED score, however, displayed a modest increase, 0.617 and 0.621, 
respectively. Restricting the study period to the last five years reduced the study population to 
78,699 patients, and essentially doubled the NRI: 20.7% (95%CI, 17.9%-23.5%). 
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Discussion 
In this nationwide cohort study reflecting clinical practice, we recalibrated the original HAS-BLED 
score to account for 2 points if the stroke type was a haemorrhagic stroke. We observed an 
improved accuracy of the recalibrated HAS-BLED score as displayed by an improved NRI of 
10.0% and a relative IDI of 23%. 
Although the recalibration only resulted in a modest increase in the C-statistics, the potential of 
improved accuracy could be higher, as we only reclassified a very small proportion of this large 
cohort: of 2,218 patients who sustained an ICH event, we reclassified 1,479 (0.7% of total study 
population). The remaining 739 patients who were not reclassified all had prior events of ischemic 
stroke/TIA and a major bleeding event (or anaemia).  
The recalibrated HAS-BLED score could potentially be more complicated to count than the original 
score. The physician who is presented with a patient who has sustain an haemorrhagic stroke has to 
take into account if this patient already has 1 point attributing prior bleeding and prior stroke. On 
the other hand, counting a haemorrhagic stroke as two points (1 for stroke and 1 for bleeding) 
appears intuitively applicable given the nature of the outcome.  Importantly, the recalibrated score 
performs best within short follow-up time in terms of NRI, which could be related to the patients 
who were actually reclassified (those with a haemorrhagic stroke); however, this could represent the 
early excess risk associated with such ‘high risk’ patients. 
This study has some limitations. We did not have access to INR values from the registries; hence 
we excluded a potential pivotal component from the HAS-BLED score. We used an observational 
design to assess the HAS-BLED score, but we cannot rule out miscoding of comorbidity and 
concomitant medication.  Additionally, we did not have access to imaging data and we cannot rule 
out erroneously coded haemorrhagic strokes. We assessed the HAS-BLED score at baseline, 
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however risk assessment in AF patients is a continuum and risk (both for bleeding and 
thromboembolic events) does not remain static in these patients.  
In conclusion, recalibration of the HAS-BLED score, counting 2 points for a haemorrhagic stroke, 
resulted in an improved accuracy of predicting major bleeding events. This approach could 
potentially aid physicians in a more accurate bleeding risk assessment in AF patients. 
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Table 1: Major bleeding event rates per 100 person-years for major bleeding events according to 
HAS-BLED scores for 1-year follow-up in incident atrial fibrillation patients. 
 Original HASBLED  Recalibrated HASBLED 
Points Person-time Events Event rate Person-time Events Event rate 
0 19611        193   0.98 19611        193 .98 
1 41864       1127   2.69 41799       1,111 2.69 
2 51933       2179   4.20 51703       2,149 4.16 
3 43769       2392   5.46 43646       2,368 5.43 
4 17359       1294   7.45 17472       1,316 7.53 
5 3692        361   9.78 3965       402 10.14 
6 425         52   12.25 456         59 12.94 
7 22         4 18.23 23          4 17.36 
8 12 0 - 22          0 - 
9 (Labile INR) NA NA NA NA NA NA 
Any score 
 
178676 7602 4.3 - - - 
Categorised risk       
0-2 (low risk) 113408 3499 3.09 113113 3453 3.05 
≥3 (High risk) 65268 4103 6.29 65563 4149 6.33 
Observation time starts after a quarantine period of 7 days relative to AF discharge. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
Online Supplement
e-Table 1: ICD codes and ATC codes used in the study. 
 
International Classification of 
Diseases 10th revision (ICD-
10) code 
Anatomical Therapeutic 
Chemical (ATC) code 
Condition   
  Hypertension  See specified definition* 
  Diabetes mellitus E10.0; E10.1; E10.9; E11.0; 
E11.1; E11.9 
A10 
  Ischemic stroke I63; I64  
  Transient ischemic disease G45  
  Abnormal renal function I12; I13; N00-N05; N07; N11; 
N14; N17-N19; Q61 
 
  Abnormal hepatic function B15.0; B16.0; B16.2; B19.0; 
K70.4; K72; K76.6; I85 
 
  Prior Bleeding I60-I62; D62; J94.2; H11.3; 
H35.6; H43.1; N02; N95; 
R04; R31; R58; K25.0; K26.0; 
K27.0; K28.0; K29.0; S06.3C; 
S06.4; S06.5; S06.6 
 
  Alcohol intake E22.4; E52.9A; F10; G31.2; 
G62.1; G72.1; I42.6; K29.2; 
K70; K86.0; L27.8A; O35.4M; 
T51; Z71.4; Z72.1 
 
  Atrial fibrillation I48   
  Major bleeding D62 J942 H113 H356 H431 
N02 N95 R04 R31 R58 
 
  Gastrointestinal bleeding K250 K260 K270 K280 K290  
  Intracranial bleeding 
  Traumatic intracranial bleeding 
  Retinal bleeding 
I60 I61 I62 
S063C S064 S065 S066 
H356 
 
Medication   
  Aspirin  B01AC06 
  Non-steroidal anti-inflammatory 
drugs 
 M01A 
 
* We identified subjects with hypertension from combination treatment with at least two of the following 
classes of antihypertensive Drugs: 
I. Alpha adrenergic blockers (C02A, C02B, C02C) 
II. Non-loop diuretics (C02DA, C02L, C03A, C03B, C03D, C03E, C03X, C07C, C07D, C08G, C09BA, C09DA, 
C09XA52) 
III. Vasodilators (C02DB, C02DD, C02DG, C04, C05)  
IV. Beta blockers (C07) 
V. Calcium channel blockers (C07F, C08, C09BB, C09DB) 
VI. Renin-angiotensin system inhibitors (C09). 
 	  
151509 
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